Thermo Fisher Scientific (NYSE:TMO) Reaches New 52-Week High - Here's Why

Key Points

• Thermo Fisher Scientific reached a new 52-week high of $704, supported by expectations for third-quarter revenue and EPS growth, stronger biotechnology and pharmaceutical activity, and demand for bioproduction and clinical research services.
• Analyst sentiment remains broadly positive, with a consensus rating of “Moderate Buy” from 26 analysts and an average price target of $654.05, though pre-earnings analysis warns the stock may face downside risk if results or guidance disappoint.
• The company reported 10.5% year-over-year quarterly revenue growth and EPS of $6.03, beating estimates, while major institutional investors—including BlackRock—expanded or initiated positions; insiders, however, sold $44.1 million of shares during the quarter.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday. The stock traded as high as $704.00 and last traded at $684.7180, with a volume of 322,369 shares. The stock had previously closed at $673.20.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Analysts expect third-quarter revenue and EPS growth, supported by demand for bioproduction products, clinical research services, product innovation and a recovery in biotechnology and pharmaceutical activity. Thermo Fisher to Report Q3 Earnings: What’s in the Cards?
• Positive Sentiment: Industry reports point to rapid growth in 3D cell-culture technologies and single-use bioprocessing assemblies—markets expected to expand at approximately 19.9% and 22.8% annually, respectively. Thermo Fisher is listed among the major suppliers positioned to benefit from these trends. Global 3D Cell Culture Technologies Market Report Single-Use Assemblies Global Market Report
• Positive Sentiment: Thermo Fisher’s clinical research business is supporting Quantum BioPharma’s Phase 2 multiple-sclerosis trial, highlighting the company’s expanding role across drug development, clinical trials and manufacturing. This provides strategic visibility, although the near-term financial impact is likely limited. Thermo Fisher’s Expanded Drug Lifecycle Role
• Neutral Sentiment: Erste Group Bank issued a fiscal 2027 earnings estimate for TMO, while other analyst coverage continues to frame the company as a high-quality life-sciences supplier. The estimate may support valuation confidence, but no specific forecast change was provided. FY2027 Earnings Estimate for TMO Issued By Erste Group Bank
• Negative Sentiment: Pre-earnings analysis cautions that Thermo Fisher lacks the combination of positive earnings-revision momentum and other indicators typically associated with a likely earnings beat. With results approaching, this creates downside risk if guidance or demand trends fall short of elevated expectations. Thermo Fisher Scientific Reports Next Week

Analysts Set New Price Targets

Several equities research analysts have recently commented on TMO shares. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, October 3rd. CLSA began coverage on Thermo Fisher Scientific in a report on Thursday, September 3rd. They issued an "outperform" rating and a C$748.00 target price on the stock. BMO Capital Markets downgraded shares of Thermo Fisher Scientific to a "market perform" rating in a research report on Wednesday, September 9th. HSBC upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 1st. Finally, Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a report on Wednesday, September 9th. They set an "overweight" rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $654.05.

Thermo Fisher Scientific Price Performance

The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The business has a 50 day simple moving average of $633.06 and a 200-day simple moving average of $545.54. The firm has a market cap of $254.63 billion, a price-to-earnings ratio of 37.03, a P/E/G ratio of 2.77 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the business posted $4.28 earnings per share. The company's quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares of the company's stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TMO. BlackRock Inc. purchased a new position in Thermo Fisher Scientific during the second quarter valued at $15,501,867,000. Bank of New York Mellon Corp purchased a new stake in shares of Thermo Fisher Scientific in the second quarter worth $1,974,561,000. Bank of America Corp DE purchased a new stake in shares of Thermo Fisher Scientific in the second quarter worth $1,952,930,000. Auto Owners Insurance Co increased its holdings in shares of Thermo Fisher Scientific by 57,845.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company's stock valued at $1,406,844,000 after acquiring an additional 2,423,706 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Thermo Fisher Scientific by 12.9% during the fourth quarter. Invesco Ltd. now owns 2,163,261 shares of the medical research company's stock valued at $1,253,501,000 after acquiring an additional 247,975 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.